Prothena Corp Public (PRTA) Non-Current Assets (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Non-Current Assets of $10.7 million in Q1 2026, down 7.91% quarter-over-quarter from $11.6 million in Q4 2025, and down 81.93% on a YoY basis from $59.2 million in Q1 2025.
Prothena Corp Public (PRTA) Non-Current Assets (2012 - 2026) Analysis & Trends
Prothena Corp Public's Non-Current Assets history runs 15 years deep, the most recent figure standing at $10.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 81.93% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $10.7 million (down 81.93% YoY), while the FY2025 annual figure was $11.6 million, down 81.18% from the prior year.
- Non-Current Assets was $10.7 million for Q1 2026 at Prothena Corp Public, down from $11.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $61.7 million in Q4 2024 to a low of $10.7 million in Q1 2026.
- Historically, Non-Current Assets has averaged $39.3 million across 5 years, with a median of $41.2 million in 2023.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets soared 88.49% in 2023, then plunged 81.93% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $38.9 million in 2022, then jumped by 46.65% to $57.1 million in 2023, then gained by 8.05% to $61.7 million in 2024, then tumbled by 81.18% to $11.6 million in 2025, then declined by 7.91% to $10.7 million in 2026.
- The last three Non-Current Assets figures came in at $10.7 million (Q1 2026), $11.6 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 10.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.69 Mn |
| Dec 31, 2025 | 11.61 Mn |
| Sep 30, 2025 | 12.65 Mn |
| Jun 30, 2025 | 13.59 Mn |
| Mar 31, 2025 | 59.16 Mn |
| Dec 31, 2024 | 61.70 Mn |
| Sep 30, 2024 | 60.27 Mn |
| Jun 30, 2024 | 59.59 Mn |
| Mar 31, 2024 | 57.33 Mn |
| Dec 31, 2023 | 57.10 Mn |
| Sep 30, 2023 | 56.32 Mn |
| Jun 30, 2023 | 43.55 Mn |
| Mar 31, 2023 | 41.24 Mn |
| Dec 31, 2022 | 38.94 Mn |
| Sep 30, 2022 | 29.88 Mn |
| Jun 30, 2022 | 28.30 Mn |
| Mar 31, 2022 | 25.79 Mn |
| Dec 31, 2021 | 24.56 Mn |
| Sep 30, 2021 | 25.17 Mn |
| Jun 30, 2021 | 26.91 Mn |